文献速递血液净化与透析

昂丹司琼与维持性血液透析患者心源性猝死风险

Ondansetron and the Risk of Sudden Cardiac Death among Individuals Receiving Maintenance Hemodialysis.
PubMed 文献 · J Am Soc Nephrol · 2024-02-27

基于美国肾脏数据系统(2012–2019)的新用药者活性对照队列研究,比较口服昂丹司琼与QT延长潜力较小的止吐药(异丙嗪、甲氧氯普胺或丙氯拉嗪)在维持性血液透析患者中的10天心源性猝死风险,发现昂丹司琼起始与更高的短期心脏风险相关。

要点

  • 在血液透析患者中,起始昂丹司琼相比QT延长潜力较小的止吐药,10天心源性猝死风险更高。
  • 调整后风险比1.44(95%CI 1.08–1.93),调整后风险差0.06%(95%CI 0.01%–0.11%)。
  • 需权衡昂丹司琼的止吐获益与短期心脏风险,尤其对QT延长高危透析患者。

核心结论

  • 在维持性血液透析患者中,起始昂丹司琼相比QT延长潜力较小的止吐药,与更高的短期心脏风险相关。

研究设计与样本

  • 新用药者、活性对照、队列研究,使用美国肾脏数据系统(USRDS)2012–2019年数据。
  • 共纳入119,254例维持性血液透析患者,其中64,978例(55%)起始昂丹司琼,54,276例(45%)起始对照止吐药。
  • 采用逆概率治疗加权生存模型估计调整风险比、风险差及95%CI,意向性治疗分析,非心源性猝死作为竞争事件。

主要发现

  • 起始昂丹司琼相比对照止吐药,10天心源性猝死调整风险比为1.44(95%CI 1.08–1.93)。
  • 调整风险差为0.06%(95%CI 0.01%–0.11%),需伤害人数(NNH)为1688。
  • 次要分析中额外心脏结局结果与主要分析一致。

临床怎么用

  • 对维持性血液透析患者处方止吐药时,需评估QT延长风险,优先考虑QT延长潜力较小的药物。
  • 起始昂丹司琼后应关注短期心脏不良事件,尤其对已有QT延长高危因素的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: In hemodialysis, ondansetron initiation versus initiation of lesser QT-prolonging antiemetics associated with higher 10-day sudden cardiac death risk. Analyses considering additional cardiac outcomes had consistent findings. BACKGROUND: Individuals receiving hemodialysis have a high incidence of sudden cardiac death and are susceptible to QT interval–prolonging medication–related cardiac complications. Ondansetron, an antiemetic with known QT-prolonging potential, is associated with fatal arrhythmias in the general population when administered intravenously. The cardiac safety of ondansetron in the hemodialysis population is unknown. METHODS: We conducted a new-user, active-comparator, cohort study using United States Renal Data System data (2012–2019) to examine the association between the initiation of oral ondansetron versus antiemetics with lesser QT-prolonging potential (promethazine, metoclopramide, or prochlorperazine) and the 10-day risk of sudden cardiac death among individuals receiving hemodialysis. We used inverse probability of treatment-weighted survival models to estimate adjusted hazard ratios, risk differences, and 95% confidence intervals (CIs). We used an intention-to-treat approach in which non-sudden cardiac death was considered a competing event. We examined additional cardiac outcomes in secondary analyses. RESULTS: Of 119,254 study patients, 64,978 (55%) initiated ondansetron and 54,276 (45%) initiated a comparator antiemetic. Initiation of ondansetron versus a comparator antiemetic was associated with higher relative and absolute 10-day risks of sudden cardiac death (adjusted hazard ratio, 1.44 [95% CI, 1.08 to 1.93]; adjusted risk difference, 0.06% [95% CI, 0.01% to 0.11%]). The number needed to harm was 1688. Analyses of additional cardiac outcomes yielded similar findings. CONCLUSIONS: Compared with initiation of antiemetics with lesser QT-prolonging potential, initiation of ondansetron was associated with higher short-term cardiac risks among people receiving hemodialysis.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Ismail S, Funk MJ, Flythe JE, et al. Ondansetron and the Risk of Sudden Cardiac Death among Individuals Receiving Maintenance Hemodialysis. J Am Soc Nephrol. 2024. PMID: 38409683. doi:10.1681/ASN.0000000000000336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。